Safety and immunogenicity of Sinovac’s prototype pandemic influenza H5N1 vaccines: a review on clinical trials

Abstract  Sinovac Biotech started to develop prototype pandemic influenza H5N1 vaccines in March 2004. On 2 April 2008, Sinovac’s inactivated, aluminium‐adjuvanted, whole‐virion prototype pandemic influenza A (H5N1) vaccine (PanFlu™) was granted production licensure by the China regulatory authority...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yuan‐Zheng, Yin, Wei‐Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634113/
https://www.ncbi.nlm.nih.gov/pubmed/19453400
http://dx.doi.org/10.1111/j.1750-2659.2008.00067.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634113/
https://www.ncbi.nlm.nih.gov/pubmed/19453400
http://dx.doi.org/10.1111/j.1750-2659.2008.00067.x

Ejemplares similares